Recruiting Clinical Trials

Displaying 31 - 40 of 213 result(s)
Study Title Condition Phase Location
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy B-Cell Acute Lymphoblastic Leukemia Phase 2
  • Country: 
    United States
  • Country: 
    Belgium
  • Country: 
    Canada
  • Country: 
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomo ... Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic Phase 3
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Australia
  • Country: 
A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy Acute Myeloid Leukemia Phase 2
  • Country: 
    United States
  • Country: 
    Canada
  • Country: 
    Germany
  • Country: 
A Phase III Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib in Combination With Osimertinib Versus Platinum - Pemetrexed Based Doublet Chemotherapy in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR Activ ... Carcinoma, Non-Small-Cell Lung Phase 3
  • Country: 
    United States
  • Country: 
    Japan
  • Country: 
    Korea, Republic of
  • Country: 
A Phase II, Multicenter, Randomized, Open Label Two Arm Study Comparing the Effect of Crizanlizumab + Standard of Care to Standard of Care Alone on Renal Function in Sickle Cell Disease Patients ≥ 16 Years With Chronic Kidney Disease Due to Sickle Ce ... Sickle Cell Disease (SCD) Phase 2
  • Country: 
    United States
  • Country: 
    Brazil
  • Country: 
    France
  • Country: 
A Randomized, Subject and Investigator Blinded, Placebo-controlled and Multi-center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients With Moderate to Severe Hidradenitis Suppurativa Hidradenitis Suppurativa Phase 2
  • Country: 
    United States
  • Country: 
    Austria
  • Country: 
    Belgium
  • Country: 
An Open-Label, Single-arm Study to Evaluate the Safety and Efficacy of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung Phase 2
  • Country: 
    China
A Randomized, Subject and Investigator Blinded, Placebo Controlled, Multi-center Study in Parallel Groups to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne Inflammatory Acne Phase 2
  • Country: 
    United States
  • Country: 
    Czech Republic
  • Country: 
    France
  • Country: 
A Three-period Multicenter Study, With a Randomized-withdrawal, Double-blinded, Placebo-controlled Design in Period 2 to Evaluate the Clinical Efficacy, Safety, and Tolerability of MAS825 in NLRC4-GOF Patients NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis) Phase 2
  • Country: 
    United States
  • Country: 
    Czech Republic
  • Country: 
    France
  • Country: 
Phase II Trial of Neoadjuvant and Adjuvant Capmatinib in Participants With Stages IB-IIIA, N2 and Selected IIIB (T3N2 or T4N2) NSCLC With MET Exon 14 Skipping Mutation or High MET Amplification (Geometry-N) Non-small Cell Lung Cancer Phase 2
  • Country: 
    United States